Results 131 to 140 of about 196,807 (276)

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9

Cytoskeleton, EarlyView.
ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook, Edna C. Hardeman, Peter W. Gunning   +2 more
wiley   +1 more source

Paclitaxel combined with platinum (PTX) versus fluorouracil combined with cisplatin (PF) in the treatment of unresectable esophageal cancer: a systematic review and meta-analysis of the efficacy and toxicity of two different regimens [PDF]

, 2023
Li’ang Xu, Xiaoxi Chen, Lan Wang, Jing Han, Qi Wang, Shutang Liu, Xiaolin Zhang, Chun Han   +7 more
openalex   +1 more source

Advanced extracellular vesicle immunotherapy

FlexMat, EarlyView.
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang, Yunfei Mu, Xianyue Ji, Xiaoting Jiang, Ruiheng Wang, Xianguang Ding, Lianhui Wang   +6 more
wiley   +1 more source

Preoperative Bevacizumab in Combination With Paclitaxel and Carboplatin in Surgically Resectable Non-Small Cell Lung Cancer

, 2011
Erin M. Bertino, Miguel A. Villalona‐Calero, Patrick Ross, Michael R. Grever, Gregory A. Otterson   +4 more
openalex   +1 more source

Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer [PDF]

, 2009
Lecia V. Sequist, Panos Fidias, Jennifer S. Temel, Tatjana Kolevska, Michael S. Rabin, Ralph V. Boccia, Howard A. Burris, Robert J. Belt, Mark S. Huberman, O.O. Melnyk, Glenn Mills, Craig W. Englund, D. Caldwell, James Keck, Lisa Meng, Marsha Jones, Gail L. Brown, Martin J. Edelman, Thomas J. Lynch   +18 more
openalex   +1 more source

Mechanisms of spinal glial activation in chemotherapy‐induced peripheral neuropathy: Focus on microglia and astrocytes

Ibrain, EarlyView.
Chemotherapy‐induced peripheral neuropathy (CIPN) remains a major clinical challenge, with central sensitization considered an important pathological mechanism in its occurrence and persistence. This review focuses on spinal astrocytes and microglia, systematically summarizing the pathological mechanisms of spinal glial cells involved in CIPN caused by
Long Gu, Song Cao, Yonghuai Feng
wiley   +1 more source

Pacific Blue Derivatives of Paclitaxel as Fluorescent Probes of OATP1B-Type Transporters. [PDF]

Clin Transl Sci
Nepal MR, Xu Y, Jin Y, Hu P, Hu X, Rane DS, Andres AE, Ahmed EA, Steiger B, Sparreboom A, Peterson BR, Hu S.   +11 more
europepmc   +1 more source

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2 [PDF]

, 2018
Ajeet Gajra, Nagla Abdel Karim, Deborah Mulford, L. Villaruz, Marc Matrana, Haythem Ali, Edgardo S. Santos, Tymara Berry, Teng Jin Ong, Alexandra Sanford, Katayoun I. Amiri, David R. Spigel   +11 more
openalex   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source

Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel–S-1–oxaliplatin and docetaxel–oxaliplatin–5-fluorouracil as first-line therapy for advanced gastric cancer

Y. Wang, Bingyang Ma, Chenguang Zhang, Yuwen Wang, Ting Pan, Cui Zhao, Baojia Cai, Pengjie Yu, Bin Guo, Jinfu Ma   +9 more
openalex   +1 more source